Open AccessPARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
Author(s) -
William P. Tew,
Christina Lacchetti,
Annie Ellis,
Kathleen Maxian,
Susana Banerjee,
Michael A. Bookman,
Monica B. Jones,
Jung Min Lee,
Stéphanie Lheureux,
Joyce F. Liu,
Kathleen N. Moore,
Carolyn Y. Muller,
Patricia Rodríguez,
Christine Walsh,
Shan N. Westin,
Elise C. Kohn
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.01924
Subject(s) - olaparib , medicine , oncology , brca mutation , ovarian cancer , bevacizumab , guideline , parp inhibitor , cancer , chemotherapy , pathology , poly adp ribose polymerase , polymerase , biology , genetics , gene
To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC).